Multitude Therapeutics is a clinical-stage biotech developing FIC/BIC ADCs by its unparalleled target and antibody discovery MabArray technology, a high-throughput screening of live cells for acquisition of new targets and lead antibodies(Sci. Adv. 2020), combined with a proprietary T1000-exatecan linker payload platform(Cancer Discov. 2023). This powerful synergy enabled Multitude to build an atlas of ADCs that has the potential to treat malignancies with high unmet medical needs.